Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Yaoyu Ning"'
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
Supplementary Figure 3 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a55a658107edbacb04f85646bc213606
https://doi.org/10.1158/1535-7163.22496250.v1
https://doi.org/10.1158/1535-7163.22496250.v1
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
The mTOR pathway is hyperactivated through oncogenic transformation in many human malignancies. Ridaforolimus (AP23573; MK-8669) is a novel rapamycin analogue that selectively targets mTOR and is currently under clinical evaluation. In this study, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1569b6d231c9801039f6c0365f86e4e7
https://doi.org/10.1158/1535-7163.c.6535203
https://doi.org/10.1158/1535-7163.c.6535203
Autor:
Victor M. Rivera, Xiaotian Zhu, Kwok-kin Wong, Shengwu Liu, Robert J. Griffin, Johara Chouitar, Michael Fitzgerald, William C. Shakespeare, David Dalgarno, Tim Clackson, Narayana I. Narasimhan, Biplab Das, Stephan G. Zech, Matthew T. Greenfield, Feng Li, Yongbo Hu, Wei-Sheng Huang, Sen Zhang, Yaoyu Ning, Sara Nadworny, Scott D. Wardwell, Shuai Li, Alexandra E. Gould, Theresa E. Baker, Sylvie Vincent, Francois Gonzalvez
Most EGFR exon 20 insertion (EGFRex20ins) driver mutations in non–small cell lung cancer (NSCLC) are insensitive to approved EGFR tyrosine kinase inhibitors (TKI). To address the limitations of existing therapies targeting EGFR-mutated NSCLC, moboc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1233d4a09c246c7e577a052bb61a6464
https://doi.org/10.1158/2159-8290.c.6549370.v1
https://doi.org/10.1158/2159-8290.c.6549370.v1
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
Supplementary Figure 1 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31157ac1340d347481ad2e92f31f6667
https://doi.org/10.1158/1535-7163.22496256
https://doi.org/10.1158/1535-7163.22496256
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
Supplementary Figure Legends from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::439392f02e858cecdc3c943bce799317
https://doi.org/10.1158/1535-7163.22496247
https://doi.org/10.1158/1535-7163.22496247
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
Supplementary Table 1 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29bf4f4d96fd3dfbf968b8c8066295f5
https://doi.org/10.1158/1535-7163.22496244.v1
https://doi.org/10.1158/1535-7163.22496244.v1
Autor:
Tim Clackson, Frank Wang, John D. Iuliucci, Narayana I. Narasimhan, Roy Pollock, Yaoyu Ning, Scott D. Wardwell, Lori Berk, David Miller, Rachel M. Squillace, Victor M. Rivera
Supplementary Figure 2 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4eeceb9b398b313ae4df947905f9c06b
https://doi.org/10.1158/1535-7163.22496253
https://doi.org/10.1158/1535-7163.22496253
Autor:
Victor M. Rivera, Xiaotian Zhu, Kwok-kin Wong, Shengwu Liu, Robert J. Griffin, Johara Chouitar, Michael Fitzgerald, William C. Shakespeare, David Dalgarno, Tim Clackson, Narayana I. Narasimhan, Biplab Das, Stephan G. Zech, Matthew T. Greenfield, Feng Li, Yongbo Hu, Wei-Sheng Huang, Sen Zhang, Yaoyu Ning, Sara Nadworny, Scott D. Wardwell, Shuai Li, Alexandra E. Gould, Theresa E. Baker, Sylvie Vincent, Francois Gonzalvez
Supplementary Tables (S1-6) and Figures (S1-6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40b1686b17282cc4afaa22ed044b1306
https://doi.org/10.1158/2159-8290.22540399
https://doi.org/10.1158/2159-8290.22540399
Autor:
Victor M. Rivera, Sebastian Bauer, Jonathan A. Fletcher, Michael C. Heinrich, Tim Clackson, Frank Wang, Anna Kohlmann, Youngchul Song, Yaoyu Ning, Scott Wardwell, Julia Ketzer, Meijun Zhu, Grant Eilers, Cesar Serrano, Tianjun Zhou, Alexa Schrock, Sadanand Vodala, Rana Anjum, Joseph M. Gozgit, Andrew P. Garner
Purpose: KIT is the major oncogenic driver of gastrointestinal stromal tumors (GIST). Imatinib, sunitinib, and regorafenib are approved therapies; however, efficacy is often limited by the acquisition of polyclonal secondary resistance mutations in K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e10487109bc325ff9193ce17784f275
https://doi.org/10.1158/1078-0432.c.6523520
https://doi.org/10.1158/1078-0432.c.6523520
Autor:
Victor M. Rivera, Sebastian Bauer, Jonathan A. Fletcher, Michael C. Heinrich, Tim Clackson, Frank Wang, Anna Kohlmann, Youngchul Song, Yaoyu Ning, Scott Wardwell, Julia Ketzer, Meijun Zhu, Grant Eilers, Cesar Serrano, Tianjun Zhou, Alexa Schrock, Sadanand Vodala, Rana Anjum, Joseph M. Gozgit, Andrew P. Garner
Supplementary methods, patient information and figure legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::624afd3155e4285f1da35f43756a4569
https://doi.org/10.1158/1078-0432.22457162
https://doi.org/10.1158/1078-0432.22457162